These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
626 related articles for article (PubMed ID: 27377311)
1. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. Glassman PM; Balthasar JP J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311 [TBL] [Abstract][Full Text] [Related]
2. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys. Glassman PM; Chen Y; Balthasar JP J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301 [TBL] [Abstract][Full Text] [Related]
3. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Cao Y; Jusko WJ J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917 [TBL] [Abstract][Full Text] [Related]
4. Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens. Glassman PM; Balthasar JP MAbs; 2017; 9(2):297-306. PubMed ID: 27892793 [TBL] [Abstract][Full Text] [Related]
5. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition. Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865 [TBL] [Abstract][Full Text] [Related]
6. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Wang J; Iyer S; Fielder PJ; Davis JD; Deng R Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767 [TBL] [Abstract][Full Text] [Related]
7. Target-mediated drug disposition model for drugs that bind to more than one target. Gibiansky L; Gibiansky E J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044 [TBL] [Abstract][Full Text] [Related]
8. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. Li L; Gardner I; Dostalek M; Jamei M AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823 [TBL] [Abstract][Full Text] [Related]
9. Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. Malik PRV; Hamadeh A; Phipps C; Edginton AN J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):277-290. PubMed ID: 28260166 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465 [TBL] [Abstract][Full Text] [Related]
11. A translational platform PBPK model for antibody disposition in the brain. Chang HY; Wu S; Meno-Tetang G; Shah DK J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858 [TBL] [Abstract][Full Text] [Related]
12. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site. Gibiansky L; Gibiansky E J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976 [TBL] [Abstract][Full Text] [Related]
13. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Shah DK; Betts AM J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261 [TBL] [Abstract][Full Text] [Related]
14. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling. Hu S; D'Argenio DZ J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362 [TBL] [Abstract][Full Text] [Related]
15. Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodies. Glassman PM; Balthasar JP Int J Pharm; 2016 May; 505(1-2):69-78. PubMed ID: 27041125 [TBL] [Abstract][Full Text] [Related]
16. Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies. Sepp A; Muliaditan M MAbs; 2024; 16(1):2324485. PubMed ID: 38700511 [TBL] [Abstract][Full Text] [Related]
17. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues. Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351 [TBL] [Abstract][Full Text] [Related]
18. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Glassman PM; Balthasar JP Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890 [TBL] [Abstract][Full Text] [Related]
19. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430 [TBL] [Abstract][Full Text] [Related]
20. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies. Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]